Author
The University of Texas MD Anderson Cancer CenterORCID 0000-0003-0511-1888Unclaimed ORCID profile · follow to get notified of new preprints
Mutual co-authors in cluster
4 papers
Recent·Most cited
Jonathan M. DeLiberty, Fan Yi Kong, Qijia Yu…·Joseph Douglas Mancias
This study identifies ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer by analyzing proteomic changes induced by KRAS inhibition and developing an antibody drug conjugate.
Amrita Barua, Samrat T. Kundu, Sofia Garza…·Don Lynn Gibbons
This study identifies PDK1 and YAP1/TEAD signaling as drivers of acquired resistance to KRAS inhibitors in NSCLC and suggests their co-targeting as a potential therapeutic strategy.
Yongkun Wei, Minghui Liu, Er-Yen Yen…·Haoqiang Ying
This study identifies CD24 as an actionable signal activated by KRASG12C inhibition in pancreatic cancer, enhancing macrophage phagocytosis and sensitizing tumors to therapy.
Kathleen M. McAndrews, Krishnan K. Mahadevan, Bingrui Li…·Raghu Kalluri
This study investigates how CDK8 remodels the tumor microenvironment to resist KRASG12D inhibition in PDAC, showing that targeting CDK8 can overcome resistance and improve survival.